Latest news with #Enhabit
Globe and Mail
5 days ago
- Business
- Globe and Mail
Enhabit (EHAB) Q2 EPS Jumps 86%
Key Points Enhabit (NYSE:EHAB) outperformed earnings estimates, posting Non-GAAP EPS of $0.13 versus the expected $0.10. Quarterly revenue (GAAP) reached $266.1 million, exceeding analyst estimates and rising 2.1% from the prior year. Full-year 2025 guidance was raised for revenue, Adjusted EBITDA (non-GAAP), and Adjusted EPS (non-GAAP), reflecting management's improved outlook. These 10 stocks could mint the next wave of millionaires › Enhabit (NYSE:EHAB), a leading US provider of home health and hospice services, released its second quarter 2025 earnings on August 6, 2025. The report highlighted a modest revenue increase and stronger-than-expected profitability, with GAAP revenue exceeding analyst estimates and non-GAAP EPS surpassing expectations. GAAP revenue was $266.1 million, above the $263.4 million analyst expectation and up from $260.6 million in the prior year period. Non-GAAP earnings per share were $0.13, beating the consensus estimate of $0.10 and up from $0.07 a year earlier. Management raised full-year guidance for revenue, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), and adjusted EPS. The quarter showcased stability in home health and accelerated growth in the hospice segment, though some profit margins declined in home health. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Business Overview and Key Success Factors Enhabit specializes in providing skilled home health and hospice care across 34 states. It delivers nursing, therapy, and specialized medical services to patients in their homes and offers end-of-life care through its hospice branches. With 249 home health and 114 hospice locations, Enhabit is one of the largest standalone operators in its sector. The business model relies on both Medicare and non-Medicare payers, blending government reimbursements with commercial contracts. Key focus areas include optimizing its mix of payer contracts, expanding value-based payment arrangements, and leveraging its dense branch network to improve operational efficiency. The company also invests heavily in predictive analytics and technology, aiming to enhance both outcomes and cost control. Success hinges on managing labor costs, navigating regulatory changes, and maintaining strong referral relationships in an aging demographic environment. Quarter in Review: Segment Results and Financial Trends Revenue (GAAP) grew 2.1%, with both segments reporting different trends. In home health, segment net service revenue (GAAP) declined 2.0% to $205.9 million, mainly due to a 4.7% drop in Medicare revenue. Non-Medicare home health revenue, however, rose 1.7% (GAAP) as payer contract strategies continued to show results. Total home health admissions grew 1.3% year over year, driven by a 5.2% rise in non-Medicare admissions. However, Medicare admissions dropped 3.7%, and recertifications, which track patients re-entering care, fell 2.7%. Profitability pressures in home health were clear. Adjusted EBITDA for the segment declined by 11.1% to $39.3 million, while the segment EBITDA margin compressed to 19.1% from 21.0% in Q2 2024. Controlling costs helped: home health cost per patient day was flat year over year despite labor market pressures. The company reduced visits per episode by 2.1% compared to Q2 2024, indicating improved efficiency but also raising questions about maintaining care quality. Revenue per episode increased 2.2%. The hospice segment provided the period's most notable gains. Hospice net service revenue (GAAP) jumped 19.4% year over year to $60.2 million. Admissions grew 8.7%, and average daily census, a critical measure of patients served each day, rose 12.3%. Segment Adjusted EBITDA (non-GAAP) reached $14.0 million, up 53.8% from the prior year. The hospice Adjusted EBITDA margin strengthened to 23.3%, up from 18.1% in Q2 2024. Cost control stood out: hospice cost per patient day increased just 1.0%, far below revenue per patient day growth of 6.3%, boosting margins. Enhabit opened three new locations in the period, signaling continued expansion. The company also paid down $10.0 million in debt, part of a broader deleveraging plan reducing overall interest expense. However, some challenging trends persist: home health Medicare census remains in decline, total segment revenue fell, and recertification rates (patients re-qualified for care) decreased. Segment Adjusted EBITDA margin in home health narrowed by 1.9 percentage points year over year (non-GAAP). On the hospice side, the discharged average length of stay slipped to 103 days from 108, a trend that may reduce profitability if it extends further. Enhabit is not a dividend-paying company. Strategy, Market Drivers, and Technology Home health care includes skilled nursing and therapy services provided to patients in their homes—an alternative to facility-based care. Hospice, in contrast, focuses on comfort and symptom management for terminally ill patients, typically provided in the patient's home. Enhabit's recent strategy prioritizes expanding payer innovation contracts—agreements that often link payments to care episodes and patient outcomes. Demographic tailwinds continue to support the industry, with the US senior population expected to reach 78.3 million by 2040. Enhabit's geographic scale, spread across 34 states, positions it to capture increasing demand for both service lines. The company's investments in technology have notable effects. It uses Medalogix Pulse, a predictive analytics platform, to optimize home health visit allocation by patient need, reducing unnecessary visits while maintaining care standards. Two internal apps, now in pilot testing, further streamline staff communication and referral management. Outlook and What to Watch Management raised its guidance for FY2025. Updated expectations for net service revenue (GAAP) are now between $1.060 and $1.073 billion for full-year 2025, compared to the previous guidance of $1.050 to $1.080 billion. Adjusted EBITDA is now guided to $104 to $108 million for 2025, up from $101 to $107 million previously. Adjusted EPS guidance increased to a range of $0.47 to $0.55 for 2025, compared to the previous range of $0.41 to $0.51. This reflects confidence in hospice momentum, continued operational efficiency, and ongoing cost control initiatives. The company did not announce any dividend policy changes, confirming it does not currently pay a dividend. For the rest of the year, investors should watch ongoing trends in home health Medicare volumes and margins, the company's success in renegotiating payer contracts, and whether technology continues to foster both productivity and quality. Contract renewals, regulatory changes, shifts in patient mix, and the impact of ongoing branch expansion all remain critical factors moving forward. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of August 4, 2025
Washington Post
5 days ago
- Business
- Washington Post
Enhabit: Q2 Earnings Snapshot
DALLAS — DALLAS — Enhabit Inc. (EHAB) on Wednesday reported second-quarter net income of $5.2 million. The Dallas-based company said it had net income of 10 cents per share. Earnings, adjusted for non-recurring costs, came to 13 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 10 cents per share.
Business Wire
5 days ago
- Business
- Business Wire
Enhabit Home Health & Hospice Announces CEO Transition Plan
DALLAS--(BUSINESS WIRE)-- Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice provider, today announced that Barb Jacobsmeyer, president and CEO, and a member of the board of directors, intends to step down from these roles in July 2026, or upon the appointment of a successor. The company has initiated a leadership succession plan with Jacobsmeyer's full support to ensure a smooth transition. The board has retained Russell Reynolds Associates, a leading executive search firm, to assist in a comprehensive search process to identify the company's next CEO. 'I am honored to have served as the first CEO of Enhabit and to have been part of the steady progress we have made together over the past several years,' said Jacobsmeyer. 'The leadership team and our entire workforce is second-to-none, and I have been inspired by our team's commitment to providing high-quality, compassionate care for our patients. I am confident in Enhabit's strategy and believe we are well-positioned to capitalize on the opportunities ahead and create shareholder value.' 'On behalf of the board, I am sincerely grateful for Barb's exceptional leadership, partnership and dedication to the company and the patients we serve,' said Jeffrey Bolton, chairman of Enhabit's board of directors. 'Barb has helped to stabilize the business during her tenure and enabled the company to build on our momentum. As we seek the right successor to drive our next phase of growth, we are committed to a smooth transition and remain focused on executing our mission.' Second Quarter 2025 Results and Conference Call In a separate press release issued today, Enhabit released its financial results for the second quarter of 2025. The company will detail its results via a webcast scheduled to begin at 10 a.m. EDT on Aug. 7, 2025. A link to the webcast of the conference call and online replay can be found on Enhabit's investor website. About Enhabit Home Health & Hospice Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 249 home health locations and 114 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit
Yahoo
17-07-2025
- Business
- Yahoo
Enhabit Home Health & Hospice Announces Date of 2025 Second Quarter Earnings Call
DALLAS, July 17, 2025--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced it will report its results for the second quarter ended June 30, 2025, on Aug. 6, 2025, and host a webcast and conference call on Aug. 7, 2025. Individuals who would like to participate in the conference call webcast should join 15 minutes before the scheduled start time. Aug. 7, 2025 10 a.m. EDT Toll-free: 888-660-6150 International: 929-203-0843 Conference ID: 5248158 Webcast link: A link to the webcast of the conference call and online replay can be found on Enhabit's investor website. About Enhabit Home Health & Hospice Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 251 home health locations and 113 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit View source version on Contacts Investor relations Bob Okunskiinvestorrelations@ 469-860-6061 Media contact Erin Volbedamedia@ 972-338-5141 Sign in to access your portfolio
Business Wire
17-07-2025
- Business
- Business Wire
Enhabit Home Health & Hospice Announces Date of 2025 Second Quarter Earnings Call
DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced it will report its results for the second quarter ended June 30, 2025, on Aug. 6, 2025, and host a webcast and conference call on Aug. 7, 2025. Individuals who would like to participate in the conference call webcast should join 15 minutes before the scheduled start time. Aug. 7, 2025 10 a.m. EDT Toll-free: 888-660-6150 International: 929-203-0843 Conference ID: 5248158 Webcast link: A link to the webcast of the conference call and online replay can be found on Enhabit's investor website. About Enhabit Home Health & Hospice Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 251 home health locations and 113 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit
